NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Genomic Medicine > Public Health Minister Visits Oxford Cancer Hospital ahead of World Cancer Day

Public Health Minister Visits Oxford Cancer Hospital ahead of World Cancer Day

4 February 2017 · Listed under Genomic Medicine, Multi-Modal Cancer Therapies

Ahead of World Cancer Day on February, Public Health Minister Nicola Blackwood highlighted the importance of UK scientific research to beating cancer during a visit to the Churchill Hospital.

The Public Health and Innovation Minister saw state-of-the-art clinical trials and facilities for new cancer treatments and patients, both supported by the NIHR Oxford Biomedical Research Centre (BRC).

The Minister visited the Early Phase Clinical Trials Unit and the radiotherapy department at the centre, where she met patients including Peter Homerston (pictured), nurses, senior clinicians and research leaders.

The Minister, also MP for Oxford West and Abingdon, said after the Friday, February 3 visit: “Oxford has a proud tradition of being at the heart of our endeavour to push the boundaries of modern medicine.

“The UK is among the very best in the world for medical and health research, and Oxford will be at the forefront of Britain’s post-Brexit scientific success.”

Oxford BRC Director Prof Keith Channon said: “We were pleased to host the minister’s visit and delighted that she could see examples of the wide range of cutting edge research in cancer, from new discoveries in genetics through to patients receiving world-first drugs in clinical trials.”

Oxford University Hospitals NHS Foundation Trust hosts the NIHR Oxford Biomedical Research Centre, a partnership between the Trust and the University of Oxford, to fund medical research.

The BRC was established in 2007 with a competitively awarded grant of £57m from the National Institute for Health Research (NIHR), funded by the Department of Health to improve the health and wealth of the nation through research.

A further grant of £95.5m was awarded from 2012 to 2017 and in September 2016 it was announced the BRC would receive £113.7m for 2017 to 2022.

The BRC has enabled numerous scientific advances and is currently funding research in 14 themes, to rise to 20 from April 2017.

These have included “bionic eye” retinal implant and gene therapy trials for blind people; leadership of the first clinical trials of Ebola vaccines during the 2014/15 outbreak and use of clinical informatics data such as through a mobile phone app to help pregnant women manage their gestational diabetes.

In cancer, Oxford has made many contributions to understanding the use of genome sequencing in cancer diagnoses and in identifying the correct treatment for a patient’s individual cancer. This has also underpinned the cancer programme in Genomics England and enabled targeted trials of many new drugs for cancer.

← Funding boost for genetics centre
Genetic sequencing offers same-day TB testing →

News

  • Study highlights ongoing COVID-19 risk in some cancer patients despite vaccination 24 May 2022
  • BRC study outlines researchers training needs and barriers 20 May 2022
  • Three new Blood and Transplant Research Units created in Oxford 18 May 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre